{"id":"NCT01808612","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing","officialTitle":"A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2014-07","completion":"2014-07","firstPosted":"2013-03-11","resultsPosted":"2015-05-12","lastUpdate":"2015-05-12"},"enrollment":513,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Fluoxetine","otherNames":["LY110140","Fluoxetine Hydrochloride","Prozac","Sarafem"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"20 mg Fluoxetine","type":"EXPERIMENTAL"},{"label":"40 mg Fluoxetine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the short-term efficacy and safety of Fluoxetine in Japanese adult participants with Major Depressive Disorder (MDD).","primaryOutcome":{"measure":"Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score","timeFrame":"Baseline, 6 weeks","effectByArm":[{"arm":"20 mg Fluoxetine","deltaMin":-6.18,"sd":0.57},{"arm":"40 mg Fluoxetine","deltaMin":-6.25,"sd":0.77},{"arm":"Placebo","deltaMin":-6.91,"sd":0.49}],"pValues":[{"comp":"OG000 vs OG002","p":"0.264"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":15},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":259},"commonTop":["Nasopharyngitis","Nausea","Somnolence","Blood creatine phosphokinase increased","Constipation"]}}